Moleculin Biotech, INC 8-K filings

Moleculin Biotech announced positive Q2 2026 financial results, highlighting significant progress in its pivotal MIRACLE trial for relapsed/refractory AML with Annamycin showing triple complete remission rates.

Moleculin Biotech, Inc. announced the closing of a public offering, raising approximately $9.3 million to fund its clinical development programs.

Moleculin Biotech announces updated preliminary blinded results from its Phase 2/3 MIRACLE trial for Annamycin in R/R AML, showing promising remission rates, especially in patients who failed prior venetoclax therapy.

Moleculin Biotech announced positive preliminary efficacy results from its Phase 2/3 MIRACLE trial, showing Annamycin treatment arms significantly outperformed the control in patients with relapsed or refractory acute myeloid leukemia.

Moleculin Biotech provides an investor presentation and reports on warrant exercises generating $2.7 million in gross proceeds.

Independent market research indicates strong physician and payer interest in Annamycin for treating relapsed/refractory AML.

Moleculin Biotech presented new clinical data at ASCO 2026 demonstrating no detectable cardiotoxicity for its lead drug candidate, Annamycin.

Moleculin Biotech, Inc. has released an investor presentation dated May 2026, detailing corporate updates and strategic information.

Moleculin Biotech announced that new pooled cardiac safety data for its lead drug candidate Annamycin will be presented at the 2026 ASCO Annual Meeting.

Moleculin Biotech announced first quarter 2026 financial results and provided a clinical update on its pivotal MIRACLE trial, highlighting early positive remission rates in AML patients.

Moleculin Biotech announces imminent unblinding of its pivotal MIRACLE trial data for Annamycin in R/R AML, with preliminary results showing significant outperformance.

Moleculin Biotech announces positive cardiac safety findings for its Annamycin drug in relapsed/refractory AML patients, suggesting it may overcome a key limitation of traditional anthracyclines.

Moleculin Biotech announced the issuance of a Hong Kong patent for its proprietary method of reconstituting liposomal Annamycin, extending protection through June 25, 2040.

Moleculin Biotech announced new preclinical data at AACR 2026 showing Annamycin significantly inhibited tumor growth and extended survival in pancreatic cancer models, with no observed cardiotoxicity.

Moleculin Biotech, Inc. announced the results of its Special Meeting of Stockholders held on April 15, 2026, where shareholders approved the issuance of shares for certain warrants but did not approve a company name change.

Moleculin Biotech announced the enrollment of its 45th subject in the pivotal Phase 2B/3 MIRACLE trial for R/R AML, setting the stage for a critical mid-2026 interim data unblinding.

Moleculin Biotech, Inc. announced it has posted its updated corporate investor presentation on its website, furnished as Exhibit 99.1 to a Form 8-K.

Moleculin Biotech reported full-year 2025 financial results and confirmed its pivotal MIRACLE trial's 45-patient interim data unblinding is on track for mid-2026, showing encouraging early results in R/R AML.

Moleculin Biotech secures up to $8.3 million in gross proceeds by inducing existing warrant holders to exercise, issuing new Series H warrants.

Moleculin Biotech, Inc. announced a notice of allowance from the Japan Patent Office for a patent covering methods for reconstituting its lead drug candidate, Annamycin.

Moleculin Biotech, Inc. stockholders approved the issuance of shares related to warrants but rejected a proposed name change to Moleculin Inc. at a Special Meeting.

Moleculin Biotech, Inc. announced it is using an investor presentation dated January 2026, available on its website.

Moleculin Biotech announced an independent assessment confirmed Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials in 90 subjects.

Moleculin Biotech announces accelerated 2026 outlook, including first pivotal trial unblinding, global expansion, and new externally funded clinical programs for Annamycin and WP1066.

Moleculin Biotech, Inc. announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement, leading to the cancellation of its delisting hearing.

Moleculin Biotech, Inc. announced warrant amendments and capital raises, significantly improving its stockholders' equity to over $10 million, addressing Nasdaq listing compliance.

Moleculin Biotech announced positive Phase 1 clinical trial results for WP1066 in pediatric recurrent malignant brain tumors, demonstrating safety and anti-tumor immune responses.

Moleculin Biotech, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported deficiency.

Moleculin Biotech, Inc. secured approximately $6.8 million in gross proceeds by inducing holders of existing Series C, D, and F warrants to exercise them in exchange for new Series G warrants.

Moleculin Biotech reports 78% enrollment for its pivotal MIRACLE Phase 2B/3 Annamycin study in R/R AML, with first unblinding expected in Q1 2026.